Concomitant methotrexate and radiotherapy in advanced head and neck cancer: 15-year follow-up of a randomized clinical trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/82502
Title:
Concomitant methotrexate and radiotherapy in advanced head and neck cancer: 15-year follow-up of a randomized clinical trial.
Authors:
Gupta, Nirmal K; Swindell, Ric
Abstract:
Long-term follow-up for patients who receive chemoradiation for head and neck cancer is lacking from most studies reported in the literature. This report gives a 15-year review of the use of concomitant methotrexate and radiation in advanced head and neck cancer. Although there has not been any significant benefit in overall survival, the primary control rate is higher in patients who received methotrexate in addition to radiotherapy. However, in those with oropharyngeal cancer, both primary control and survival were significantly improved when chemotherapy was used. The other most significant benefit from chemoradiation is the much lower rate of salvage operations for primary recurrence. The addition of methotrexate failed to show any effect on the development of metastatic neck nodes. The rate of block dissection of the neck was similar in both arms of the study and is comparable with the historical data collected at this institute. There has not been any significant increase in serious late morbidity. The timing of the methotrexate with radiotherapy has a significant influence on primary control and survival in head and neck cancer.
Affiliation:
Christie Hospital, Manchester, UK.
Citation:
Concomitant methotrexate and radiotherapy in advanced head and neck cancer: 15-year follow-up of a randomized clinical trial. 2001, 13 (5):339-44 Clin Oncol (R Coll Radiol)
Journal:
Clinical Oncology
Issue Date:
2001
URI:
http://hdl.handle.net/10541/82502
PubMed ID:
11716226
Type:
Article
Language:
en
ISSN:
0936-6555
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorGupta, Nirmal K-
dc.contributor.authorSwindell, Ric-
dc.date.accessioned2009-09-24T11:55:04Z-
dc.date.available2009-09-24T11:55:04Z-
dc.date.issued2001-
dc.identifier.citationConcomitant methotrexate and radiotherapy in advanced head and neck cancer: 15-year follow-up of a randomized clinical trial. 2001, 13 (5):339-44 Clin Oncol (R Coll Radiol)en
dc.identifier.issn0936-6555-
dc.identifier.pmid11716226-
dc.identifier.urihttp://hdl.handle.net/10541/82502-
dc.description.abstractLong-term follow-up for patients who receive chemoradiation for head and neck cancer is lacking from most studies reported in the literature. This report gives a 15-year review of the use of concomitant methotrexate and radiation in advanced head and neck cancer. Although there has not been any significant benefit in overall survival, the primary control rate is higher in patients who received methotrexate in addition to radiotherapy. However, in those with oropharyngeal cancer, both primary control and survival were significantly improved when chemotherapy was used. The other most significant benefit from chemoradiation is the much lower rate of salvage operations for primary recurrence. The addition of methotrexate failed to show any effect on the development of metastatic neck nodes. The rate of block dissection of the neck was similar in both arms of the study and is comparable with the historical data collected at this institute. There has not been any significant increase in serious late morbidity. The timing of the methotrexate with radiotherapy has a significant influence on primary control and survival in head and neck cancer.en
dc.language.isoenen
dc.subjectHead and Neck Canceren
dc.subject.meshAntimetabolites, Antineoplastic-
dc.subject.meshCarcinoma, Squamous Cell-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshFollow-Up Studies-
dc.subject.meshGreat Britain-
dc.subject.meshHead and Neck Neoplasms-
dc.subject.meshHumans-
dc.subject.meshMethotrexate-
dc.subject.meshSalvage Therapy-
dc.subject.meshSurvival Analysis-
dc.subject.meshTime Factors-
dc.titleConcomitant methotrexate and radiotherapy in advanced head and neck cancer: 15-year follow-up of a randomized clinical trial.en
dc.typeArticleen
dc.contributor.departmentChristie Hospital, Manchester, UK.en
dc.identifier.journalClinical Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.